Sosei Heptares Operational Highlights and Consolidated Results for the First Quarter 2020

Sosei Heptares Operational Highlights and Consolidated Results for the First Quarter 2020

PR Newswire

TOKYO and LONDON, May 13, 2020

TOKYO and LONDON, May 13, 2020 /PRNewswire/ -- Sosei Group Corporation ("the Company"; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2020. The full report can be accessed by clicking here.

Operational Highlights for Q1 2020

Post-period Highlights

Financial Highlights for the Three-month Period ended 31 March 2020

*Convenience conversion to US$ at the following rates: 2020: 1US$ =108.907 JPY; 2019: 1US$ =110.226 JPY

**Non-IFRS measure

Shinichi Tamura, Chairman, President and CEO of Sosei Heptares, commented: "Our operating environment has changed dramatically in recent months as a result of the SARS-CoV-2 pandemic. I am very pleased to report that the company has responded extremely well to these changes by rapidly implementing practises to keep our staff, and other parties with whom we interact, safe and prevent any further spread of the virus; this is our main priority. The measures we have put in place have also ensured a high level of business continuity and enabled us to work on revenue-generating collaborations and other areas of key importance to our business. I am impressed with and extremely grateful to our staff for the level of dedication and commitment they have shown, which has allowed them to deliver outstanding results and scientific achievements in these unprecedented circumstances."

About Sosei Heptares

We are an international biopharmaceutical group focused on the discovery and early development of new medicines originating from our proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities. We are advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including CNS, immuno-oncology, gastroenterology, inflammation and other rare/specialty indications.

We have established partnerships with some of the world's leading pharmaceutical companies, including Allergan, AstraZeneca, Daiichi-Sankyo, Genentech (Roche), Novartis, Pfizer and Takeda; and with innovative biotechnology companies, including Kymab, MorphoSys and PeptiDream. Sosei Heptares is headquartered in Tokyo, Japan with R&D facilities in Cambridge, UK.

"Sosei Heptares" is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR® are trademarks of Sosei Group companies.

For more information, please visit

LinkedIn: @soseiheptaresco | Twitter: @soseiheptaresco | YouTube: @soseiheptaresco

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialization of products. Various risks may cause Sosei Group Corporation's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


Sosei Heptares 

Shinichiro Nishishita – VP Investor Relations

Candelle Chong
VP Corporate Strategy and Communications

Citigate Dewe Rogerson

Yas Fukuda – Japanese Media

Mark Swallow, David Dible – International Media


Voltar noticias em Inglês